

## **Alert** | Health Care & FDA Practice



April 2024

### **FDA Reminds Stakeholders of Animal Drug ‘Approved by FDA’ Labeling Requirements**

On April 1, 2024, the U.S. Food and Drug Administration (FDA) issued a **statement** reminding stakeholders, especially animal drug manufacturers and veterinarians, of certain labeling requirements for approved animal drugs, which had previously been subject to the agency’s enforcement discretion.

Specifically, section 502(w)(3) of the Federal Food, Drug and Cosmetic Act (as amended by the Animal Drug User Fee Act and Animal Generic Drug User Fee Act of 2018) requires the statement “Approved by FDA” to appear on the labeling of approved animal drugs. This requirement applies to both brand name animal drugs and generic animal drugs, and requires use of specific language, as applicable:

- For brand name animal drugs: “Approved by FDA under NADA # XXX-XXX”
- For generic animal drugs: “Approved by FDA under ANADA # XXX-XXX”

While FDA considers any approved animal drug not bearing the applicable language to be misbranded, it had previously **exercised enforcement discretion** for this requirement until March 30, 2024, due to stakeholder feedback citing, among other concerns, supply chain issues impacting compliance with the Sept. 30, 2023, deadline.

FDA’s recent statement also notes the parallel labeling requirement for Type A medicated articles (i.e., animal drugs that are used to manufacture medicated feeds), except for so-called Blue Bird labels under

21 C.F.R. § 514.1(b)(3)(v)(b) (i.e., representative labeling prepared as a guide for final medicated animal feed labels).

Along with FDA's recent statement, FDA also issued a "Dear Veterinarian" **letter** explaining these requirements in an effort to help veterinarians distinguish between approved and unapproved animal drugs.

Manufacturers of both brand name and generic animal drugs should immediately ensure compliance with this labeling requirement due to the risk of FDA enforcement action (e.g., warning letter), now that FDA no longer intends to exercise enforcement discretion regarding this requirement.

## Author

This GT Alert was prepared by:

- **Nicholas J. Diamond** ‡ | +1 713.374.3557 | [Nick.Diamond@gtlaw.com](mailto:Nick.Diamond@gtlaw.com)

‡ Admitted in the District of Columbia. Not admitted in Texas. Practice in Texas limited to federal FDA, FTC, and USDA and proceedings before federal agencies.

Albany. Amsterdam. Atlanta. Austin. Berlin. † Boston. Charlotte. Chicago. Dallas. Delaware. Denver. Fort Lauderdale. Houston. Kingdom of Saudi Arabia. † Las Vegas. London. \* Long Island. Los Angeles. Mexico City. † Miami. Milan. † Minneapolis. New Jersey. New York. Northern Virginia. Orange County. Orlando. Philadelphia. Phoenix. Portland. Sacramento. Salt Lake City. San Diego. San Francisco. Seoul. † Shanghai. Silicon Valley. Singapore. † Tallahassee. Tampa. Tel Aviv. † Tokyo. † United Arab Emirates. † Warsaw. † Washington, D.C.. West Palm Beach. Westchester County.

*This Greenberg Traurig Alert is issued for informational purposes only and is not intended to be construed or used as general legal advice nor as a solicitation of any type. Please contact the author(s) or your Greenberg Traurig contact if you have questions regarding the currency of this information. The hiring of a lawyer is an important decision. Before you decide, ask for written information about the lawyer's legal qualifications and experience. Greenberg Traurig is a service mark and trade name of Greenberg Traurig, LLP and Greenberg Traurig, P.A. †Greenberg Traurig's Berlin office is operated by Greenberg Traurig Germany, an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. \*Operates as a separate UK registered legal entity. †Greenberg Traurig operates in the Kingdom of Saudi Arabia through Greenberg Traurig Khalid Al-Thebity Law Firm, a professional limited liability company, licensed to practice law by the Ministry of Justice. †Greenberg Traurig's Mexico City office is operated by Greenberg Traurig, S.C., an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. †Greenberg Traurig's Milan office is operated by Greenberg Traurig Santa Maria, an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. †Operates as Greenberg Traurig LLP Foreign Legal Consultant Office. †Greenberg Traurig's Singapore office is operated by Greenberg Traurig Singapore LLP which is licensed as a foreign law practice in Singapore. †Greenberg Traurig's Tel Aviv office is a branch of Greenberg Traurig, P.A., Florida, USA. †Greenberg Traurig's Tokyo Office is operated by GT Tokyo Horitsu Jimusho and Greenberg Traurig Gaikokuhojimubengoshi Jimusho, affiliates of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. †Greenberg Traurig's United Arab Emirates office is operated by Greenberg Traurig Limited. †Greenberg Traurig's Warsaw office is operated by GREENBERG TRAUIG Nowakowska-Zimoch Wysokiński sp.k., an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. Certain partners in GREENBERG TRAUIG Nowakowska-Zimoch Wysokiński sp.k. are also shareholders in Greenberg Traurig, P.A. Images in this advertisement do not depict Greenberg Traurig attorneys, clients, staff or facilities. No aspect of this advertisement has been approved by the Supreme Court of New Jersey. ©2024 Greenberg Traurig, LLP. All rights reserved.*